Labcorp (LH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
04-29

For the quarter ended March 2025, Labcorp (LH) reported revenue of $3.35 billion, up 5.3% over the same period last year. EPS came in at $3.84, compared to $3.68 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.41 billion, representing a surprise of -2.04%. The company delivered an EPS surprise of +2.95%, with the consensus EPS estimate being $3.73.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net book-to-bill Ratio ( TTM Book-to-Bill): 1.1% versus 1% estimated by two analysts on average.
  • Revenues- Biopharma Laboratory Services: $721.30 million compared to the $742.69 million average estimate based on four analysts. The reported number represents a change of +1.5% year over year.
  • Revenues- Diagnostics Laboratories: $2.63 billion compared to the $2.69 billion average estimate based on four analysts. The reported number represents a change of +6.1% year over year.
  • Adjusted Operating Income- Biopharma Laboratory Services: $106.90 million versus $108.86 million estimated by three analysts on average.
  • Adjusted Operating Income- Diagnostics Laboratories: $427.50 million versus the three-analyst average estimate of $435.69 million.
View all Key Company Metrics for Labcorp here>>>

Shares of Labcorp have returned -1.4% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Labcorp (LH) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10